Our company

Our company

Core Therapeutic Areas

Our therapy areas

Full Value Chain

Full Value Chain

Career

Career

简 繁
Corporate News
NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication
2023-11-15
EDDING announced that the applications for drug approval of lusutrombopag have been officially accepted in Mainland China
2021-12-07
Edding Shares Topline Data —— Pivotal Phase III Study of Lusutrombopag in Mainland China
2021-09-23
EDDING announced that the applications for drug approval of VASCEPA® have been officially accepted in Mainland China
2021-02-09
Edding Shares Topline Data —— Pivotal Phase III Study of VASCEPA® in Mainland China
2020-11-20
Eddingpharm's subsidiary Suzhou Ceclor Pharmaceutical Co., Ltd. is officially unveiled
2019-11-25
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
2019-06-24
U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
2019-06-17
Eddingpharm Get Two Legacy Antibiotics Brands and Manufacturing Facility in China
2019-04-22
Eddingpharm announces an exclusive agreement with Roche China for the promotion and distribution of Recormon® in China
2018-03-12
Eddingpharm announces an exclusive agreement with Lilly China for the promotion and distribution of Ceclor® and Vancocin® in China
2016-11-09
Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa® (icosapent ethyl) in China
2015-03-03
Media Center
2019-11-13
活动回顾
亿腾医药收英文
2019-12-03
Media Center
Company Overview
Download
Media kit
Download
Unit 122-129, Building A3, No. 700, Wanrong Road， Shanghai，China

pr@eddingpharm.com

沪ICP备2021007464号

Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038